New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates

Adult Male Science Protozoan Proteins Antigens, Protozoan Protein Structure, Secondary 03 medical and health sciences Malaria Vaccines Malaria, Vivax Humans Amino Acid Sequence 0303 health sciences Immunodominant Epitopes Q R Membrane Proteins Middle Aged 3. Good health Case-Control Studies Immunoglobulin G Antibody Formation Medicine Epitopes, B-Lymphocyte Female Peptides Plasmodium vivax Research Article
DOI: 10.1371/journal.pone.0258637 Publication Date: 2021-11-02T17:56:08Z
ABSTRACT
Peptide-based vaccines have demonstrated to be an important way to induce long-lived immune responses and, therefore, a promising strategy in the rational of vaccine development. As to malaria, among the classic vaccine targets, the Apical membrane antigen (AMA-1) was proven to have important B cell epitopes that can induce specific immune response and, hence, became key players for a vaccine approach. The peptides selection was carried out using a bioinformatic approach based on Hidden Markov Models profiles of known antigens and propensity scale methods based on hydrophilicity and secondary structure prediction. The antigenicity of the selected B-cell peptides was assessed by multiple serological assays using sera from acute P.vivax infected subjects. The synthetic peptides were recognized by 45.5%, 48.7% and 32.2% of infected subjects for peptides I, II and III respectively. Moreover, when synthetized together (tripeptide), the reactivity increases up to 62%, which is comparable to the reactivity found against the whole protein PvAMA-1 (57%). Furthermore, IgG reactivity against the tripeptide after depletion was reduced by 42%, indicating that these epitopes may be responsible for a considerable part of the protein immunogenicity. These results represent an excellent perspective regarding future chimeric vaccine constructions that may come to contemplate several targets with the potential to generate the robust and protective immune response that a vivax malaria vaccine needs to succeed.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (54)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....